Characterisation of seven medications approved for attention-deficit/hyperactivity disorder using in vitro models of hepatic metabolism. (3rd July 2022)

• Record Type: Journal Article
• Authors: Law, Rebecca; Lewis, David; Hain, Daniel; Daut, Rachel; DelBello, Melissa P.; Frazier, Jean A.; Newcorn, Jeffrey H.; Nurmi, Erika; Cogan, Elizabeth S.; Wagner, Susanne; Johnson, Holly; Lanchbury, Jerry
• Is Part Of: Xenobiotica. Volume 52:Number 7(2022)
• Page Start: 676
• Page End: 686
• Publication Date: 2022-07-03
• Subjects: ADHD -- cytochrome P450 (CYP450) -- uridine 5′-diphospho-glucuronosyltransferase (UGT) -- pharmacokinetics -- hepatocytes -- human liver microsomes (HLMs) -- chemical inhibition -- in vitro; Metabolism -- Periodicals; Drugs -- Physiological effect -- Periodicals; Food additives -- Periodicals; Chemicals -- Physiological effect -- Periodicals; Biochemistry -- Periodicals; Pharmaceutical Preparations -- metabolism -- Periodicals; Metabolism -- Periodicals; 574.133
• DOI: 10.1080/00498254.2022.2141151
• Languages: English
• ISSNs: 0049-8254

Abstract

Abstract: The metabolism of most medications approved for the treatment of attention deficit/hyperactivity disorder (ADHD) is not fully understood. In vitro studies using cryopreserved, plated human hepatocytes (cPHHs) and pooled human liver microsomes (HLMs) were performed to more thoroughly characterise the metabolism of several ADHD medications. The use of enzyme-specific chemical inhibitors indicated a role for CYP2D6 in atomoxetine (ATX) metabolism, and roles for CYP3A4/5 in guanfacine (GUA) metabolism. The 4-hydroxy-atomoxetine and N-desmethyl-atomoxetine pathways represented 98.4% and 1.5% of ATX metabolism in cPHHs, respectively. The 3-OH-guanfacine pathway represented at least 2.6% of GUA metabolism in cPHHs, and 71% in HLMs. The major metabolising enzyme for methylphenidate (MPH) and dexmethylphenidate (dMPH) could not be identified using these methods because these compounds were too unstable. Hydrolysis of these medications was spontaneous and did not require the presence of protein to occur. Clonidine (CLD), amphetamine (AMPH), and dextroamphetamine (dAMPH) did not deplete substantially in cPHHs nor HLMs, suggesting that these compounds may not undergo considerable hepatic metabolism. The major circulating metabolites of AMPH and dAMPH (benzoic acid and hippuric acid) were not observed in either system, and therefore could not be characterised. Additionally, inhibition experiments suggested a very minimal role for CYP2D6 in CLD and AMPH metabolism.